The Experts below are selected from a list of 14883 Experts worldwide ranked by ideXlab platform
Neal D Shore - One of the best experts on this subject based on the ideXlab platform.
-
chemotherapy for prostate cancer when should a urologist refer a patient to a Medical Oncologist
Prostate Cancer and Prostatic Diseases, 2013Co-Authors: Neal D ShoreAbstract:Chemotherapy for prostate cancer: when should a urologist refer a patient to a Medical Oncologist?
-
Chemotherapy for prostate cancer: When should a urologist refer a patient to a Medical Oncologist
Prostate Cancer and Prostatic Diseases, 2013Co-Authors: Neal D ShoreAbstract:The last few years have seen considerable evolution in treatment options and therapeutic strategies for patients with castrate-resistant prostate cancer (CRPC). One major change was the expansion of chemotherapeutic options with the approval of cabazitaxel, representing the first chemotherapeutic therapy after docetaxel to demonstrate improved survival in patients with CRPC. A number of other noncytotoxic therapies have either recently been approved or are in advanced development for treating this patient population. Offering novel mechanisms of action, these new agents make considerably more expansive and complex the decisions regarding when to treat, which agents to use, and the order in which they are administered. A pivotal decision point for urologists who treat patients with advanced prostate cancer has been timing the patient's referral to an Oncologist for chemotherapy. Although clinical guidelines regard chemotherapy as only appropriate for prostate cancer patients with symptomatic metastatic disease, increasing evidence points to the possibility that a subgroup of patients may benefit from an earlier introduction of chemotherapy. At the same time, additional treatment options that may either precede chemotherapy or follow initial chemotherapeutic failure mean that urologists must closely monitor their patients' health status to match specific clinical profiles with specific treatment options. With the increase in number and variety of therapeutic approaches, the role of the urologist has been expanded, in part, owing to the opportunity for urologists to administer treatments previously unavailable, and also owing to the growing importance of working cooperatively with Oncologists and as a member of a multidisciplinary team.
Jean Paul Atallah - One of the best experts on this subject based on the ideXlab platform.
-
what we know about surgical therapy in early stage non small cell lung cancer a guide for the Medical Oncologist
Cancer management and research, 2017Co-Authors: Sassine Ghanem, Sandy El Bitar, Sami Hossri, Chanudi Weerasinghe, Jean Paul AtallahAbstract:: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were Medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables.
Arif Hussain - One of the best experts on this subject based on the ideXlab platform.
-
the impact of time of Medical Oncologist visit on survival among elderly patients with stage iv prostate cancer an analysis using seer medicare data
Journal of Clinical Oncology, 2016Co-Authors: C D Mullins, Ebere Onukwugha, B Seal, Arif HussainAbstract:e17509 Background: The association between physician referrals and treatment receipt has been established in other disease settings. The impact of time to a Medical Oncologist or hematologist/oncol...
-
Effect of urologists and Medical Oncologists on treatment of elderly men with Stage IV prostate cancer.
Urology, 2011Co-Authors: Eberechukwu Onukwugha, C. Daniel Mullins, Van Doren Hsu, Brian S. Seal, Arif HussainAbstract:Objectives To examine, among elderly men with incident advanced prostate cancer (PCa), their treatment, in general, and chemotherapy, in particular, in association with a posturologist Medical Oncologist/hematologist (PUMOH) visit. The role of specialists in the management of advanced PCa is evolving in response to positive chemotherapy trials of PCa. Methods Linked Surveillance, Epidemiology, and End results and Medicare data included patients with Stage IV PCa diagnosed from 1994 to 2002 who had visited a urologist after the diagnosis and received treatment. The visits and treatment were examined, comparing patients with and without PUMOH visits. Results Most (77%) patients received treatment of their PCa and 85% of treated patients had a subsequent visit with a urologist, of whom 91% saw the urologist first (n = 5435). Of these, 43% saw only the urologist, 41% saw a Medical Oncologist/hematologist, and 32% saw a radiation Oncologist. Of the 5435 patients, 16% received chemotherapy and the adjusted odds of chemotherapy receipt were 7.2 times greater (95% confidence interval 6.0-8.7, P P P = .14) among the groups. Conclusions The results of our study have shown that nearly one quarter of men with Stage IV PCa receive no PCa treatment. Although a PUMOH visit is a significant predictor of chemotherapy receipt, many men with advanced PCa received chemotherapy without a Medical Oncologist/hematologist visit. Black American and elderly men were less likely to receive chemotherapy for advanced PCa.
Jean Klastersky - One of the best experts on this subject based on the ideXlab platform.
-
Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer
Current Opinion in Oncology, 2018Co-Authors: Gil Awada, Jean KlasterskyAbstract:PURPOSE OF REVIEW: The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting. These immunotherapies are associated with a distinct toxicity profile based on autoimmune organ toxicity which is a new challenge for supportive care during treatment with these drugs. RECENT FINDINGS: The differential diagnosis of events occurring during immune checkpoint inhibitor treatment is broad: they can be due to immune-related or nonimmune-related adverse events, atypical tumor responses (pseudoprogression or hyperprogression) or events related to comorbidities or other treatments. SUMMARY: The management of these patients includes a thorough baseline clinical, biological and radiologic evaluation, patient education, correct follow-up and management by a multidisciplinary team with a central role for the Medical Oncologist. Immune-related toxicities should be managed according to available guidelines.
Sassine Ghanem - One of the best experts on this subject based on the ideXlab platform.
-
what we know about surgical therapy in early stage non small cell lung cancer a guide for the Medical Oncologist
Cancer management and research, 2017Co-Authors: Sassine Ghanem, Sandy El Bitar, Sami Hossri, Chanudi Weerasinghe, Jean Paul AtallahAbstract:: Lung cancer remains the leading cause of death in cancer patients. The gold standard for the treatment of early-stage non-small-cell lung cancer is lobectomy with mediastinal lymph-node dissection or systematic lymph-node sampling. The evidence behind this recommendation is based on the sole randomized controlled trial conducted to date, done by the Lung Cancer Study Group and published in 1995, which found a superiority for lobectomy over sublobar resection with regard to local recurrence rate and improved survival. The population studied at that time were Medically fit patients at low risk for surgery with a stage IA non-small-cell lung carcinoma, ie, a solitary tumor less than 3 cm in size. In practice, however, thoracic surgeons have continued to push the limit of a more conservative surgical resection in this patient population. Since then, several retrospective studies have attempted to identify the ideal population to benefit from sublobar resection without it affecting survival or local recurrence. Several variables have been studied, including tumor size, patient age, surgical approach, histological and radiological properties, and optimal surgical resection margin, as well as promising prognostic biomarkers. In this review, we summarize the data available in the literature regarding the surgical approach to patients with stage IA non-small-cell lung cancer studying all the aforementioned variables.